stockchase picture

Compiling comments that experts make about stocks while on public TV.

There are 0 registered members and 1068 guests viewing this site

Company Index

List by Company Name

All | 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

List by Symbol

All | 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Abbott Labs

Stock Symbol: ABT-N

Last Price Recorded: 36.5900 on 2013-05-18 01:14:01

Globe 200 day average
Google Discussions (view only)
yahoo discussion
Date Signal Expert Opinion Price
2012-09-25 HOLD Jeff Black

Great quality company. They are splitting their medical devices and pharmaceuticals but if you own, stay the course. Likes the space. Have executed well.

 Price:
$69.570
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
BEARISH
Owned:
Yes
2012-10-11 TOP PICK David Burrows

2.9% dividend. Going down the path into splitting into two businesses. The pharma business has a higher than industry growth rate. Best performing sector in the market at present. The patent cliff is here and priced into the stock price.


 Price:
$69.420
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Yes
2012-09-14 HOLD David Driscoll

They are going to split off their medical device and their pharmaceutical division. This is in kind of a Hold mode right now until the split comes through. This is a company that has raised its dividend historically. Free cash flow is a very good. When the split comes, hang on to both shares. You’ll probably see your average cost base cut in half.

 Price:
$68.270
Subject:
GLOBAL
Bias:
DEFENSIVE
Owned:
No
2012-08-07 BUY David Baskin

(Market Call Minute.) Broadly diversified healthcare company with proprietary drugs, non-prescription drugs and medical devices. Growing nicely

 Price:
$66.030
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2012-07-09 COMMENT Christine Poole Will be splitting the company into 2 parts, pharma side and medical devices. Purchased a generic company out of India last year and India will be providing health care to the general population but will only pay for generic drugs . Currently within a couple of dollars of her target price so she might shave some of her holdings.
Price:
$65.610
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2012-10-24 COMMENT Gordon Reid

Going to spin off the pharma portion and their nutritional and diagnostic group. When they first announced the spinoff, the stock was in the mid-$50’s so it has done fairly well but it has come down on earnings. You have to be careful with spinoffs as they are technically designed for US holders and US taxation. Sold his holdings about 6 months ago.

 Price:
$65.560
Subject:
US EQUITIES
Bias:
BULLISH
Owned:
No
2012-09-04 TOP PICK Hap (Robert) Sneddon FCSI

Has got a really good pipeline and well owned by institutions.  Great triple A balance sheet and a good yield.  Screens well against S&P stocks.  Slight sideways action.  Company will be splitting into two components in the future.  This will unlock value.

 Price:
$65.460
Subject:
TECHNICAL ANALYSIS
Bias:
CAUTIOUS
Owned:
Yes
2012-11-30 TOP PICK Chyanne Fickes

Splitting as of Jan 2nd.  Trading ‘as is’ in December.  ‘New Abbot’ is their nutritional, diagnostics, vascular and diversified business, very solid sales outlooks.  Thinks there is more upside in the Drug exploration part.  Humera is one of the 5 biggest drugs globally.  5 drugs in clinical trials.  A really good pipeline. 

 Price:
$65.000
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2012-11-12 BUY Gavin Graham

(Market Call Minute) Sell off is because it is going to split itself up which will realize value.

 Price:
$64.870
Subject:
NORTH AMERICAN - LARGE & GLOBAL EQUITIES
Bias:
BULLISH on EMERGING MARKETS
Owned:
Yes
2012-11-26 TOP PICK Brian Acker, CA

You can buy at its model price and when the company splits up it would increase value.  The balance sheet has high growth parts buried within it.  These smaller parts create more value.  The pieces are worth more than the whole.  40 increases in dividends and very shareholder friendly.  He would stay with both after the split until you can review balance sheets.

 Price:
$64.360
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Yes
2012-12-03 BUY Barry Schwartz

It already had a bump up in price, but he is planning on holding both parts.  Buying for new clients.

 Price:
$64.290
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2012-11-21 SELL Gordon Reid

(Market Call Minute) Would sell on the split.  It is too complicated to be there with the split.

 Price:
$63.330
Subject:
US EQUITIES
Bias:
SELECTIVE
Owned:
Unknown
2012-11-19 TOP PICK Mohsin Bashir

12 drugs under patent after a current one comes off patent.  A hepatitis drug is about to come out as well.  It could hit its 52 week high.

 Price:
$62.920
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
Yes
2012-05-17 TOP PICK David Burrows This has been one of the strong companies in the ethical drug companies. Have grown their dividend 10% at year over the last 10 years. Has been a very steady company. Traded sideways for 12 years in a price range and recently in the last year, broke out. They are going to split this company into a medical products/devices company and a pure pharma business. The pharma business will have a high yield attached and the other part has opportunities for efficiencies and growth.
 Price:
$62.230
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2012-05-09 WAIT Gordon Reid (Market Call Minute.) Splitting in two. Their pharma business is going to be priced more cheaply but be careful because their major drug is 47% of this. To concentrated. He would look at the other piece when they split.
 Price:
$61.230
Subject:
US EQUITIES
Bias:
BULLISH on US MARKET
Owned:
No
Showing 1 to 15 of 61 entries
First Previous 1 2 3 4 5 Next Last

No Comments.

You must be logged in to comment.